Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 10:52:16 AM Fri, 27 Mar 2020   Contact Information Andy Futreal Associated Profiles  Department Chair, Professor, Genomic Medicine, UT MD Anderson Cancer Center   MDA 3SCR6.3434 (Unit 0091)    afutreal@mdanderson.org     713.794.4764    Web Link    Mutation, Neoplasms, Genes, Breast Neoplasms, Neoplasm Genes, Genome, Ovarian Neoplasms, Exome    Associated Profiles Professional Preparation Research and Expertise Affiliations Appointments  Professional Preparation  Degree Major Institution Year  PhD Pathology University of North Carolina, Chapel Hill 1993  BS Biology University of North Carolina, Charlotte 1987  Research and Expertise Research Interests   Dr. Andrew Futreal aims to accelerate the translation of genomic technologies into therapeutic applications. Before joining MD Anderson in July 2012, he was the co-director of the Cancer Genome Project at the Wellcome Trust Sanger Institute, where he continues to be an honorary faculty member. His chief scientific accomplishments include the identification of the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes, leading a pioneering effort in large-scale systematic cancer genomics leading to the identification the BRAF mutations in melanoma, ERBB2 mutations in non-small cell lung cancer and multiple new cancer genes in renal cell carcinoma. He has published over 182 papers in peer-reviewed journals. He received the NIH Public Service Award in 1995 for discovering the BRCA1 gene involved in subsets of breast and ovarian cancer. At MD Anderson, Dr. Futreal applies his knowledge of cancer genomics to improve both short-term and long-term patient outcomes extending to cancer survivorship. He is a platform leader for genomics and informatics for the Moonshot initiative. The big challenge in sifting through patient genomic data to mine clinically useful information is comprehending heterogeneity. Not only are tumors heterogeneous from one patient to another, but there is also intratumor heterogeneity—a state where subclonal subpopulations within the same tumor accumulate different kinds of mutations over time. All these factors make genomic data interpretation a task of mammoth complexity, and he plans to tackle it by integrating datasets from patient populations and analyzing them across time to identify genomic determinants of response, resistance, toxicity and survival in order to improve patient outcomes.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia Gulf Coast Cluster for Single Cell Omics  Appointments Title Department / School Institution Department Chair, Professor Genomic Medicine UT MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.